ENTPD5 and diabetic kidney disease: More importantly, mechanistic studies in DKD have shown that hyperglycemia activates the hexosamine biosynthesis pathway (HBP), which promotes or inhibits SP1 O-glycosylation through a negative feedback mechanism, thereby regulating ENTPD5 expression at the transcriptional level.